|
KMID : 0383820090660030198
|
|
Tuberculosis and Respiratory Diseases
2009 Volume.66 No. 3 p.198 ~ p.204
|
|
|
Acquired Drug Resistance during Standardized Treatment with First-line Drugs in Patients with Multidrug-Resistant Tuberculosis
|
|
Jeon Doo-Soo
Park Seung-Kyu
Kim Do-Hyung
Hwang Su-Hee
Min Jin-Hong
Kang Hyung-Seok
Sung Nack-Moon
|
|
|
Abstract
|
|
|
Background:First-line drugs, if sensitive, are the most potent drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB). This study examined the frequency and risk factors associated with acquired drug resistance to first-line drugs during a standardized treatment using first-line drugs in patients with MDR-TB.
Methods:This study included patients who were diagnosed with MDR-TB at the National Masan Tuberculosis Hospital between January 2004 and May 2008, treated with standardized first-line drugs, and for whom the preand post-treatment results of the drug susceptibility test were available. Their medical records were reviewed retrospectively.
Results:Of 41 MDR-TB patients, 14 (34.1%) acquired additional resistance to ethambutol (EMB) or pyrazinamide (PZA). Of 11 patients initially resistant to isoniazid (INH) and rifampicin (RFP), 3 (27.3%) acquired additional resistance to both EMB and PZA, and 3 (27.3%) to PZA. Of 18 patients initially resistant to INH, RFP and EMB, 6 (33.3%) acquired additional resistance to PZA. Of 6 patients initially resistant to INH, RFP and PZA, 2 (33.3%) acquired additional resistance to EMB. Ten of the 41 MDR-TB patients (24.4%) changed from resistant to susceptible. No statistically significant risk factors associated with acquired resistance could be found.
Conclusion:First-line drugs should be used cautiously in the treatment of MDR-TB in Korea considering the potential acquisition of drug resistance.
|
|
|
KEYWORD
|
|
|
Tuberculosis, Multidrug resistance, Drug resistance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|